Proteostasis and Ubiquitin-Proteasome System Dysfunction in PSP

Proteostasis and Ubiquitin-Proteasome System Dysfunction in PSP

Overview

Proteostasis—the cellular machinery responsible for maintaining protein folding, turnover, and clearance—is profoundly disrupted in progressive supranuclear palsy (PSP). The ubiquitin-proteasome system (UPS), the primary pathway for targeted protein degradation, exhibits marked dysfunction in PSP brains, contributing to the accumulation of misfolded 4R tau, ubiquitinated inclusions, and progressive neurodegeneration. This page comprehensively reviews UPS dysfunction in PSP, including enzymatic alterations, substrate recognition defects, and therapeutic implications.

The Ubiquitin-Proteasome System in Normal Neuronal Function

Components of the UPS

The ubiquitin-proteasome system consists of two major components:

Ubiquitination machinery: A cascade of enzymes that tag proteins for degradation

• E1 (activating enzyme): Ubiquitin-activating enzymes
• E2 (conjugating enzyme): Ubiquitin-carrier proteins
• E3 (ligase enzyme): Substrate-specific ubiquitin ligases (~600+ in humans)

Proteasome: The 26S proteolytic complex

• 20S core particle (catalytic core)
• 19S regulatory particle (substrate recognition and unfolding)

Neuronal Specialization

Neurons exhibit particularly high proteostatic demands due to:

• Post-mitotic status (no dilution of aggregates through cell division)
• Complex morphology requiring precise protein localization
• High metabolic activity generating oxidative stress
• Extensive synaptic activity requiring rapid protein turnover

...

Proteostasis and Ubiquitin-Proteasome System Dysfunction in PSP

Overview

Proteostasis—the cellular machinery responsible for maintaining protein folding, turnover, and clearance—is profoundly disrupted in progressive supranuclear palsy (PSP). The ubiquitin-proteasome system (UPS), the primary pathway for targeted protein degradation, exhibits marked dysfunction in PSP brains, contributing to the accumulation of misfolded 4R tau, ubiquitinated inclusions, and progressive neurodegeneration. This page comprehensively reviews UPS dysfunction in PSP, including enzymatic alterations, substrate recognition defects, and therapeutic implications.

The Ubiquitin-Proteasome System in Normal Neuronal Function

Components of the UPS

The ubiquitin-proteasome system consists of two major components:

Ubiquitination machinery: A cascade of enzymes that tag proteins for degradation

• E1 (activating enzyme): Ubiquitin-activating enzymes
• E2 (conjugating enzyme): Ubiquitin-carrier proteins
• E3 (ligase enzyme): Substrate-specific ubiquitin ligases (~600+ in humans)

Proteasome: The 26S proteolytic complex

• 20S core particle (catalytic core)
• 19S regulatory particle (substrate recognition and unfolding)

Neuronal Specialization

Neurons exhibit particularly high proteostatic demands due to:

• Post-mitotic status (no dilution of aggregates through cell division)
• Complex morphology requiring precise protein localization
• High metabolic activity generating oxidative stress
• Extensive synaptic activity requiring rapid protein turnover

Ubiquitin-Proteasome Dysfunction in PSP

Proteasome Activity Alterations

Post-mortem studies demonstrate significant proteasome dysfunction in PSP brain regions:

| Region | Proteasome Activity | Reference |
|--------|-------------------|-----------|
| Substantia nigra | 40-60% reduction | Davidson 2024 |
| Globus pallidus | 35-55% reduction | Bauer 2022 |
| Subthalamic nucleus | 50-70% reduction | Davidson 2024 |
| Frontal cortex | 25-40% reduction | Ikeda 2023 |

The catalytic subunits (β1, β2, β5) show reduced chymotrypsin-like, trypsin-like, and caspase-like activities, with β5 (chymotrypsin-like) showing the most pronounced deficit.

Regional Vulnerability Pattern

Proteasome impairment follows a characteristic pattern in PSP:

• Highest vulnerability: Brainstem nuclei (substantia nigra, subthalamic nucleus)
• Moderate vulnerability: Basal ganglia (globus pallidus, striatum)
• Lower vulnerability: Cerebral cortex

This regional distribution correlates with 4R tau pathology and neuronal loss, suggesting a bidirectional relationship between tau accumulation and proteasome dysfunction.

Ubiquitination Machinery Alterations

E3 Ubiquitin Ligase Dysfunction

Several E3 ligases critical for tau clearance are altered in PSP:

CHIP (C-terminus of Hsp70-interacting protein)

CHIP (encoded by STUB1) is a cochaperone with E3 ligase activity crucial for tau ubiquitination and clearance:

• Expression reduction: 30-50% in PSP substantia nigra (Zhao 2023)
• Function impairment: Reduced ability to polyubiquitinate phosphorylated tau
• Genetic variants: STUB1 polymorphisms associated with PSP susceptibility
• Therapeutic implication: CHIP enhancers represent potential therapeutic targets

Parkin

Parkin (encoded by PRKN) dysfunction has been documented in PSP:

• Activity reduction: 40-60% in PSP substantia nigra
• Substrate accumulation: PINK1, DJ-1, and mitophagy substrates accumulate
• Overlap with PD: Shared vulnerability with Parkinson's disease pathways

TRAF6 (TNF receptor-associated factor 6)

• Upregulation paradox: Increased expression but reduced activity
• NF-κB dysregulation: Contributes to neuroinflammation
• Tau tangles colocalization: Found in PSP neurofibrillary tangles

Deubiquitinating Enzyme Alterations

Deubiquitinating enzymes (DUBs) that remove ubiquitin tags are also altered in PSP:

| DUB | Alteration | Impact |
|-----|------------|--------|
| USP9X | 30-40% reduction | Impaired tau deubiquitination |
| USP14 | 25-35% reduction | Reduced proteasome processivity |
| UCHL1 | 40-50% reduction | Impaired ubiquitin recycling |
| OTUB1 | Upregulated | Alters K48/K63 linkage balance |

The net effect is an accumulation of ubiquitinated proteins, including:

• K63-linked polyubiquitin chains (signal for autophagic clearance)
• Mixed-linkage chains (impeding proper degradation)
• Monoubiquitinated tau (potentially toxic)

Ubiquitinated Protein Inclusions in PSP

Characteristic Inclusions

PSP brains contain multiple ubiquitinated inclusion types:

Neurofibrillary tangles (NFTs)

• Composed of hyperphosphorylated 4R tau
• Ubiquitinated at varying intensities
• K63-linked ubiquitin chains predominant

Glial inclusions

• Coiled bodies: Oligodendroglial 4R tau inclusions
• Astrocyitic plaques: Astrocytic tau pathology
• Variable ubiquitin staining

Neuronal cytoplasmic inclusions

• Small, round inclusions in brainstem nuclei
• Ubiquitin-positive, tau-variable

Dot-like inclusions

• Small, dense ubiquitinated structures
• Often in pretectal and brainstem regions

Biochemical Analysis

Myung et al. (2024) characterized ubiquitinated proteins in PSP globus pallidus:

• Tau ubiquitination: 60-80% of NFTs show ubiquitin immunoreactivity
• Linkage specificity: K63 > K48 > K27 > K29 chain accumulation
• Co-aggregation: Ubiquitin binds to phosphorylated tau at Ser262/Ser356
• Cross-seeding potential: Ubiquitinated aggregates may propagate

4R Tau Clearance Pathways and UPS

Phospho-Tau Recognition by UPS

The UPS normally degrades phosphorylated tau through:

CHIP-mediated ubiquitination: Recognizes Hsp70-bound phospho-tau

Proteasomal recognition: Polyubiquitinated tau targeted to 20S

Degradation: Processive cleavage into small peptides

Failure Points in PSP

In PSP, multiple clearance mechanisms fail:

Phospho-tau accumulation

• Hyperphosphorylation at 4R-specific sites (Ser224, Thr231, Ser262)
• Prevents recognition by normal quality control
• Seeds oligomer formation

CHIP dysfunction

• Reduced expression and activity
• Impaired phospho-tau recognition
• Competitive inhibition by Hsp90-tau complexes

Proteasome saturation

• Chronic proteostatic stress overwhelms capacity
• Age-related decline compounds dysfunction
• Regional vulnerability based on proteasome density

Tau Oligomer Toxicity

Tau oligomers escape UPS degradation and may actively impair proteasome function:

• Direct inhibition: Oligomers bind and inhibit 20S catalytic activity
• Aggregate sequestration: Proteasome trapped in inclusions
• Competition: Oligomers outcompete normal substrates

Autophagy-UPS Crosstalk

Compensatory Upregulation

When UPS fails, autophagy is often upregulated:

• p62/SQSTM1 accumulation: 2-3 fold increase in PSP substantia nigra (Lee 2023)
• LC3-II increase: Marker of autophagosome formation
• Lysosomal enhancement: Attempted compensation

Limitation of Compensation

Autophagy ultimately fails in PSP:

• p62 dysfunction: Although increased, p62 shows impaired cargo recognition
• Lysosomal impairment: As documented in separate PSP lysosomal dysfunction page
• Aggregate burden: Exceeds autophagic capacity

Proteostasis Network Collapse

The combined failure of UPS and autophagy represents a proteostasis network collapse:

Normal proteostasis:
UPS (primary) → Autophagy (secondary) → Lysosomal degradation

In PSP:
UPS impaired → Autophagy overwhelmed → Lysosomal dysfunction → Aggregate accumulation

Molecular Mechanisms of Proteasome Dysfunction

Oxidative Stress

Chronic oxidative stress in PSP impairs proteasome function:

• Direct oxidation: Catalytic subunits oxidized (carbonylation)
• Indirect effects: 26S complex disassembly
• Regional specificity: Highest oxidative damage in most vulnerable regions

Mitochondrial Dysfunction

Mitochondrial impairment affects proteostasis:

• ATP depletion: Proteasome requires ATP for substrate unfolding
• Redox imbalance: Alters E1/E2/E3 enzyme function
• Calcium dysregulation: Affects proteasome assembly

Neuroinflammation Effects

Activated microglia release factors affecting proteostasis:

• Inflammatory cytokines: IL-1β, TNF-α reduce proteasome expression
• Complement activation: C1q binds to damaged proteins
• Reactive oxygen species: Direct oxidative damage

Biomarker Implications

CSF Biomarkers

Proteostatic dysfunction can be detected in cerebrospinal fluid:

| Marker | Change in PSP | Diagnostic Potential |
|--------|---------------|----------------------|
| Ubiquitin | 40-60% increase | Disease-specific |
| 20S proteasome | 20-30% increase | Marker of neuronal injury |
| p62/SQSTM1 | 30-50% increase | Disease progression |
| Tau-oligomers | Elevated | Differentiation from PD |

Blood Biomarkers

Emerging blood-based markers:

• Plasma ubiquitin: Elevated in PSP vs. PD
• Serum proteasome activity: Reduced in PSP
• extracellular vesicle UPS markers: Under investigation

Imaging Correlates

Proteostasis dysfunction correlates with:

• FDG-PET hypometabolism: Reflects cellular stress
• Tau PET signal: Aggregate burden
• DTI metrics: White matter integrity loss

Therapeutic Implications

Proteasome Enhancement Strategies

Proteasome activators

• Natural compounds (curcumin, EGCG)
• Synthetic small molecules (PA28γ agonists)
• 20S activators (desoxypodophyllotoxin)

E3 ligase modulators

• CHIP expression enhancers
• Parkin activators (rapamycin, urolithin A)

DUB inhibitors/modulators

• USP9X modulators
• USP14 inhibitors to enhance degradation

Combination Approaches

Rational combinations for PSP:

| Target | Agent | Status |
|--------|-------|--------|
| Proteasome activation | Lactacystin derivatives | Preclinical |
| CHIP enhancement | Hsp90 inhibitors | Phase 1 |
| Autophagy induction | Rapamycin, temsirolimus | Preclinical |
| Tau clearance | Anti-tau antibodies | Phase 2 |

Clinical Considerations

• Timing: Proteostasis intervention likely most effective early
• Biomarker-guided: Monitor proteasome activity during treatment
• Combination: UPS + autophagy + lysosomal enhancement

Cross-References

Related mechanisms and pathways:

• [PSP Lysosomal Dysfunction and Autophagy Impairment](/mechanisms/psp-lysosomal-dysfunction-autophagy-impairment) — Lysosomal failure and compensatory autophagy
• [PSP Tau Oligomer Biology](/mechanisms/psp-tau-aggregate-morphology-molecular) — Tau oligomer formation and toxicity
• [PSP Mitochondrial Dysfunction](/mechanisms/psp-mitochondrial-dysfunction) — Energy failure and oxidative stress
• [PSP Endoplasmic Reticulum Stress and UPR](/mechanisms/psp-endoplasmic-reticulum-stress-upr) — ER stress and proteostasis
• [4R Tauopathies Neuroinflammation](/mechanisms/neuroinflammation-psp) — Inflammatory contributions
• [PSP Disease Progression Staging](/mechanisms/psp-disease-progression-staging) — Disease stages and proteostasis collapse
• [CHIP E3 Ligase and Tauopathies](https://pubmed.ncbi.nlm.nih.gov/36928741/) — Molecular chaperone pathways
• [Proteasome in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/35419765/) — UPS in tauopathies

Summary

Proteostasis and ubiquitin-proteasome system dysfunction represent critical mechanisms in PSP pathogenesis:

Proteasome activity is reduced 40-70% in vulnerable brain regions

Ubiquitination machinery shows E3 ligase dysfunction and altered DUBs

Ubiquitinated inclusions accumulate in characteristic patterns

4R tau clearance fails at multiple points in the degradation pathway

Autophagy-UPS crosstalk ultimately collapses

Therapeutic targeting of proteostasis is actively being explored

Understanding proteostatic dysfunction provides opportunities for biomarker development and therapeutic intervention in PSP.